SCHEMBL2093372

SCHEMBL2093372

CCC(C)Oc1cccc(NC([O])=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TSHR P16473 2/20 0.48
PLAU P00749 1/20 0.46
HPGD P15428 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 2/20 0.44
POLB P06746 1/20 0.44
CA2 P00918 1/20 0.44
MTNR1B P49286 4/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ATM Q13315 1/20 0.44
THRB P10828 1/20 0.44
MTNR1A P48039 3/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094011 0.84 ALDH1A1 (0.45) ALDH1A1TSHRPLAUHPGDMEN1
SCHEMBL2093222 0.84 CA2 (0.58) ALDH1A1TSHRPLAUMEN1KMT2A
SCHEMBL2089916 0.83 GLA (0.50) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL11599863 0.80 F2R (0.60) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL11588011 0.79 KMT2A (0.54) PLAUHPGDMEN1KMT2ANPC1
SCHEMBL2093034 0.79 MTNR1A (0.40) ALDH1A1TSHRPLAUMEN1KMT2A
SCHEMBL11665507 0.78 GPBAR1 (0.55) ALDH1A1TSHRMAPTMTNR1BHSD17B10
SCHEMBL2095225 0.77 TP53 (0.68) ALDH1A1TSHRHPGDKMT2ANPC1
SCHEMBL2098249 0.75 MEN1 (0.51) ALDH1A1TSHRHPGDMEN1KMT2A
SCHEMBL2094620 0.74 KMT2A (0.51) TSHRHPGDMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885TSHR 162/4885PLAU 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.